Ikarian Capital, LLC
Holdings History for Avalo Therapeutics, Inc. - Common Stock (AVTX)
- Symbol
- AVTX on Nasdaq
- Investment type
- Equity / Common Stock
- Latest Disclosed Shares Owned
- 711,967 shares
- Security Ownership %
- 3.8%
Shares, Excluding Options vs Price
Value, Excluding Options
Ikarian Capital, LLC ownership in Avalo Therapeutics, Inc. Common Stock (AVTX)
14 Nov 2025 - Ikarian Capital, LLC has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 711,967 shares of Avalo Therapeutics, Inc. Common Stock (AVTX).
This represents 3.8% ownership of the company.
In their previous filing dated 15 May 2025, Ikarian Capital, LLC had reported owning 1,191,957 shares, indicating a decrease of +40%.
.
| Reporting Name | Ownership % | Change | Value $ | Shares owned | Change | Activity % | Price | Form | Report date | Filing time |
|---|---|---|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC | 3.8% | -62% | $9,049,101 | 711,967 | -479,990 | -40% | $12.71 | 13G/A | 30 Sep 2025 | 14 Nov 2025, 18:26 |
| Ikarian Capital, LLC | 10% | $5,959,785 | 1,191,957 | $5.00 | 13G/A | 31 Mar 2025 | 15 May 2025, 17:33 |
| Holdings date | Option | Weight | Change | Value $ | Shares | Change | Activity % | Price | All Holders |
|---|---|---|---|---|---|---|---|---|---|
| 31 Dec 2025 | 0.07% | -0.3% | $564,885 | 31,106 | -128,671 | -81% | $18.16 | Q4 2025 | |
| 31 Dec 2025 | call | 0.21% | +0.21% | $1,055,096 | 58,100 | +58,100 | NEW | $18.16 | Q4 2025 |
| 30 Sep 2025 | 0.46% | +0.36% | $2,030,766 | 159,777 | +124,477 | +353% | $12.71 | Q3 2025 | |
| 30 Jun 2025 | 0.06% | -0.27% | $176,147 | 35,300 | -164,700 | -82% | $4.99 | Q2 2025 | |
| 31 Mar 2025 | 0.52% | -2% | $1,602,000 | 200,000 | -770,259 | $8.01 | Q1 2025 | ||
| 31 Dec 2024 | 2.1% | -0% | $7,209,024 | 970,259 | -100 | -0.01% | $7.43 | Q4 2024 | |
| 30 Sep 2024 | 2.9% | +2.7% | $9,218,411 | 970,359 | +915,629 | +1673% | $9.50 | Q3 2024 | |
| 30 Jun 2024 | 0.22% | +0.03% | $682,483 | 54,730 | +8,082 | +17% | $12.47 | Q2 2024 | |
| 31 Mar 2024 | 0.28% | +0.28% | $1,014,594 | 46,648 | +46,648 | NEW | $21.75 | Q1 2024 |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.